MCL1 and acute myeloid leukemia: We found that only the combination of venetoclax and MCL1 inhibitor S63845 induced cell death with equal efficacy in AML cells grown in the absence or presence of bone marrow stroma, indicating a potential advantage of applying this combination in the treatment of AML, as this may eradicate leukemic stem cells in the bone marrow.